REPROCELL is thrilled to celebrate a groundbreaking milestone by our partner Gameto, who recently announced the birth of the first baby born using Fertilo, a proprietary in vitro oocyte maturation technology. This major medical advancement marks a pivotal breakthrough in redefining women’s healthcare, supported by our StemRNA™ Clinical induced Pluripotent Stem Cells (iPSCs).
StemRNA Clinical Seed iPSCs were used in the cellular engineering and manufacturing processes for Fertilo. By leveraging our advanced stem cell technology, Gameto developed a highly pure and potent population of ovarian support cells (OSCs), essential for maturing eggs outside the body. These OSCs closely mimic the natural support cells of the ovary, aimed at improving in vitro fertilization (IVF) and egg freezing outcomes and offer promising potential for clinical applications.
The Fertilo procedure is a faster, safer, and more accessible option for families considering assisted reproduction technology (ART) such as IVF and reduces the side-effects of traditional high-dose hormone treatments. The manuscript detailing this groundbreaking work, “Reproducible differentiation of pure ovarian support cells from clinical grade hiPSCs as a novel infertility treatment,” highlights the robustness and scalability of REPROCELL’s stem cell platform.
We’re proud to play a pivotal role in advancing women’s health and fertility through our StemRNA Clinical Seed iPSCs. As Gameto advances into a Phase 3 clinical trial in the U.S., we are committed to support their mission to drive transformative breakthroughs in regenerative medicine.
About Fertilo
Fertilo, Gameto’s lead investigational program, is a solution derived from induced pluripotent stem cells (iPSC) and designed to mature eggs outside of the body as part of minimal hormonal stimulation cycles for in vitro fertilization and egg freezing. Gameto’s goal in developing Fertilo is to make fertility treatments more convenient, safer, and accessible for a wider patient population. Fertilo has received different regulatory classifications in foreign jurisdictions, and after consultation with national regulators, has been cleared for commercialization in Australia and in large markets in Latin America.
About Gameto
Gameto is a biotechnology company developing novel treatment solutions for women’s health, starting with infertility. Gameto brings together an experienced scientific management team with the vision and passion to develop a product suite to support women throughout their reproductive journeys. Gameto’s lead program, Fertilo, aims to make IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections by maturing eggs outside of the body. Gameto is led by physician-turned-entrepreneur Dina Radenkovic as CEO and serial entrepreneur and founder of one of North America’s largest fertility networks Prelude Fertility, Martin Varsavsky, as Chairman. For more information, go to gametogen.com or follow us on Twitter and Instagram @gametogen and on LinkedIn.
About REPROCELL
REPROCELL is a life sciences company passionate about translational medicine. As experts in stem cell technologies, 3D cell culture, and human tissue research, our aim is to bridge the gap between bench and bedside. REPROCELL’s products and services provide clinically relevant solutions for your life sciences research needs. For more information, see www.reprocell.com.
See Business Wire press release: Gameto Announces World’s First Live Birth Using Fertilo Procedure that Matures Eggs Outside the Body